Targeting Cell Survival Factors, HSF1 and HSPs, with a Specific Inhibitor for Cancer Therapy

Targeting Cell Survival Factors, HSF1 and HSPs, with a Specific Inhibitor for Cancer Therapy
复制标题

使用特定抑制剂靶向细胞生存因子、HSF1 和 HSP 进行癌症治疗

DOI:
10.3191/thermalmed.33.1
复制
发表时间:
2017
期刊:
Thermal Medicine
影响因子:
--
通讯作者:
K. Ohtsuka
K. Ohtsuka
中科院分区:
--
文献类型:
--
作者:
K. Ohtsuka

文献摘要

参考文献

被引文献

相似文献

已知主要的热休克蛋白如Hsp 90和Hsp 70及其转录因子HSF 1在广泛的癌细胞中过表达。然而,其生物学意义尚不清楚。最近,人们已经认识到,HSF 1和HSP是细胞存活因子,并且对于癌细胞的发展和进展是必需的,并且HSF 1-HSP系统似乎被癌细胞在应激条件(低氧浓度、低营养、低pH)下为了它们自身的存活而增选。根据这一概念,已经建议用特异性抑制剂靶向HSF 1和HSPs用于癌症治疗。自1990年以来,Hsp 90抑制剂的研究不仅在基础研究方面,而且在临床I期、II期、甚至III期试验中也有应用。最近,已有几种用于癌症治疗的Hsp 70和HSF 1抑制剂的报道。本文综述了以HSF 1和HSPs为靶点的特异性抑制剂在肿瘤治疗中的基础研究进展。
It has been known that major heat shock proteins, such as Hsp90 and Hsp70, and their transcription factor HSF1 are overexpressed in a wide range of cancer cells. Its biological significance, however, remains unclear. Recently, it has been recognized that HSF1 and HSPs are cell survival factors and essential for cancer cell development and progression, and the HSF1-HSPs system seems to be co-opted by cancer cells for their own survival under stressful conditions (low oxygen concentration, low nutrient, low pH). According to this conception, targeting HSF1 and HSPs with a specific inhibitor has been suggested for cancer therapy. Hsp90 inhibitors have long been studied from 1990ʼ not only in a basic research but also in clinical phase I, phase II, even phase III trials. Recently, several inhibitors of Hsp70 and HSF1 for the purpose of cancer therapy have been reported. In this review, basic researches aimed for cancer therapy targeting these survival factors (HSF1 and HSPs) with a specific inhibitor are summarized.
DOI: 10.1021/bi801637q
发表时间: 2009-01-20
期刊: Biochemistry
影响因子: 2.9
作者:
Yin Z;Henry EC;Gasiewicz TA
通讯作者: Gasiewicz TA
DOI: 10.1073/pnas.78.2.1067
发表时间: 1981-02
影响因子: 11.1
作者:
H. Oppermann;W. Levinson;J. Bishop
通讯作者: H. Oppermann;W. Levinson;J. Bishop
DOI: 10.1158/0008-5472.can-06-3350
发表时间: 2007-02-01
期刊: CANCER RESEARCH
影响因子: 11.2
作者:
Aziz, Moammir H.;Manoharan, Herbert T.;Verma, Ajit K.
通讯作者: Verma, Ajit K.
Hsp90抑制剂Ganetespib在crizotinib敏感和耐抗MET驱动的肿瘤模型中与MET激酶抑制剂Crizotinib协同作用。
DOI: 10.1158/0008-5472.can-13-1156
发表时间: 2013-12-01
期刊: Cancer research
影响因子: 11.2
作者:
Miyajima N;Tsutsumi S;Sourbier C;Beebe K;Mollapour M;Rivas C;Yoshida S;Trepel JB;Huang Y;Tatokoro M;Shinohara N;Nonomura K;Neckers L
通讯作者: Neckers L
DOI: 10.1016/j.molcel.2009.09.023
发表时间: 2009-10-09
期刊: MOLECULAR CELL
影响因子: 16
作者:
Leu, J. I-Ju;Pimkina, Julia;Frank, Amanda;Murphy, Maureen E.;George, Donna L.
通讯作者: George, Donna L.